Cited by 94Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients

Open access
for the Alzheimer’s Disease Neuroimaging Initiative, Brendel, Matthias, Pogarell, Oliver, Xiong, Guoming, Delker, Andreas, Bartenstein, Peter, Rominger, Axel·2015·European Journal of Nuclear Medicine and Molecular Imaging

Abstract

Purpose Late-life depression even in subsyndromal stages is strongly associated with Alzheimer's disease (AD). Furthermore, brain amyloidosis is an early biomarker in subjects who subsequently suffer from AD and can be sensitively detected by amyloid PET. Therefore, we aimed to compare amyloid load and glucose metabolism in subsyndromally depressed subjects with mild cognitive impairment (MCI).Methods [(18)F]AV45 PET, [(18)F]FDG PET and MRI were performed in 371 MCI subjects from the Alzheimer's Disease Neuroimaging Initiative Subjects were judged β-amyloid-positive (Aβ+; 206 patients) or β-amyloid-negative (Aβ-; 165 patients) according to [(18)F]AV45 PET. Depressive symptoms were assessed by the Neuropsychiatric Inventory Questionnaire depression item 4. Subjects with depressive symptoms (65 Aβ+, 41 Aβ-) were compared with their nondepressed counterparts. Conversion rates to AD were analysed (mean follow-up time 21.5 ± 9.1 months) with regard to coexisting depressive symptoms and brain amyloid load.Results Aβ+ depressed subjects showed large clusters with a higher amyloid load in the frontotemporal and insular cortices (p < 0.001) with coincident hypermetabolism (p < 0.001) in the frontal cortices than nondepressed subjects. Faster progression to AD was observed in subjects with depressive symptoms (p < 0.005) and in Aβ+ subjects (p < 0.001). Coincident depressive symptoms additionally shortened the conversion time in all Aβ+ subjects (p < 0.005) and to a greater extent in those with a high amyloid load (p < 0.001).Conclusion Our results clearly indicate that Aβ+ MCI subjects with depressive symptoms have an elevated amyloid load together with relative hypermetabolism of connected brain areas compared with cognitively matched nondepressed individuals. MCI subjects with high amyloid load and coexistent depressive symptoms are at high risk of faster conversion to AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00259-014-2975-4

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Initiative, F. T. A. D. N., Brendel, M., Pogarell, O., Xiong, G., Delker, A., Bartenstein, P., & Rominger, A.
Affiliations
  • Ludwig-Maximilians-Universität München (DE)
  • Munich Cluster for Systems Neurology (DE)
Corresponding author
Rominger, Axel
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2015-01-29
Volume
42
Issue
5
Pages
716-724
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W2041468825
Cited by
94
References
46
Citations by year
2026: 2 · 2025: 8 · 2024: 11 · 2023: 7 · 2022: 10 · 2021: 7 · 2020: 13 · 2019: 7 · 2018: 6 · 2017: 8 · 2016: 9 · 2015: 4 · 2014: 2
FWCI
7.31
Type
journal article
Language
en
Open access
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Department of Defense
  • National Institutes of Health (5u01ag024904-10)
  • National Institute on Aging (U01-AG-024904, U19AG024904)
  • National Institute of Biomedical Imaging and Bioengineering
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
depressive symptoms, mild cognitive impairment, Alzheimer's disease, amyloid-beta, amyloid PET, FDG-PET, glucose metabolism, cognitive decline, conversion to Alzheimer's disease, insula, geriatric depression
MeSH terms
Aged, Aged, 80 and over, Depression, Female, Humans, Male, Case-Control Studies, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography, Plaque, Amyloid, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review